Lipum (publ), a clinical stage biopharmaceutical company focused on chronic inflammatory diseases, today announced that the Board of Directors has appointed Ola Sandborgh as new Chief Executive Officer, effective from 1 December 2023.

Ola Sandborgh has more than three decades of experience from the pharmaceutical industry where he has worked in leading roles in different commercial, innovation and business development positions in companies such as Pfizer, Sanofi Pasteur MSD and, most recently, as Vice President Immunology & Specialty Care at Swedish Orphan Biovitrum (Sobi). Ola has been leading global cross functional teams as well as coordinating partnerships with numerous of companies, contributing in several early to late-stage development projects and acquiring a significant experience within M&A ́s and DD ́s.

Chairman of the Board Ulf Björklund comments this step in Lipums development: “Ola brings with him a wealth of useful experience to lead our company and development activities. He has a solid background within immunology and has been involved in the development and commercialisation of several anti-inflammatory products. Ola will take over a well-run organisation from Einar Pontén, who over the past seven years successfully has transformed Lipum into a publicly listed clinical stage company. I would like to thank Einar for an excellent commitment and contribution to Lipum”.

Einar Pontén is leaving his executive role as CEO upon his own request, but still very dedicated he will take a part time business development role to facilitate a smooth transfer of responsibilities and to support further activities.

“Lipum is a unique company and a very interesting innovative player in the anti-inflammatory field. With a strong scientific background revealing that the novel target molecule BSSL plays an important role in inflammation, Lipum is on an exciting journey. I am delighted to be appointed as CEO and look forward to being leading the Lipum team on this path of strong innovation and development to the benefit for patients with inflammatory disorders, which also will create value for the shareholders of Lipum,” says Ola Sandborgh